Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small cell lung cancer: a Kansai Clinical Oncology Group study.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Lung Cancer

• Publication date

  2004-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.LUNGCAN.2003.12.001PMID 15140549
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.

  2005cited by this paper
• Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial.

  2002cited by this paper
• Phase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancer.

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxel

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.

  2001cited by this paper
• Interim analysis of a phase II study of induction weekly paclitaxel/carboplatin regimens followed by maintenance weekly paclitaxel for advanced and metastatic non-small cell lung cancer.

  2001cited by this paper
• Weekly paclitaxel in advanced non-small cell lung cancer.

  2001cited by this paper
• Single-agent versus combination chemotherapy in advanced non-small cell lung cancer (NSCLC): A CALGB randomized trial of efficacy, quality of life, and cost-effectiveness

  2001cited by this paper
• Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

  2001cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Recent developments in weekly paclitaxel therapy in lung cancer

  2001cited by this paper
• 進行肺非小細胞癌に対するCarboplatin+Weekly Paclitaxel併用療法の用量設定試験

  2001cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Phase II multicenter randomized trial of induction weekly paclitaxel (P) administered in combination with carboplatin (C) followed by weekly maintenance P vs. observation for patients (pts.) with advanced & metastatic non-small cell lung cancer (NSCLC)

  2000cited by this paper
• Diseases of the breast

  2000cited by this paper
• New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.

  1998cited by this paper
• Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer.

  1998cited by this paper
• Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study.

  1998cited by this paper
• Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.

  1997cited by this paper
• Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.

  1997cited by this paper
• Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations.

  1997cited by this paper
• Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer.

  1996cited by this paper
• Phase I study with a weekly 1 h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer.

  1996cited by this paper
• Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death.

  1996cited by this paper
• Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

  1994cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines.

  1993cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Phase II trial of carboplatin in non-small cell lung cancer.

  1986cited by this paper
• Creatinine Clearance: Bedside Estimate

  1973cited by this paper
• Letter: Creatinine clearance: bedside estimate.

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs

  2017cites this paper
• Estudio de genes y proteínas de autofagia en tumores del sistema nervioso central

  2016cites this paper
• Carboplatin plus Weekly Paclitaxel with Bevacizumab for First-line Treatment of Non-small Cell Lung Cancer.

  2016cites this paper
• RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.

  2015cites this paper
• Chemotherapy (Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin) in Elderly Patients with Non-Small Cell Lung Cancer

  2014cites this paper
• Adjuvant Chemotherapy of Gemcitabine plus Carboplatin versus Paclitaxel plus Carboplatin in Patients with Resected Non-Small Cell Lung Cancer

  2013cites this paper
• Comparative analysis of carboplatin and paclitaxel combination chemotherapy schedules in previously untreated patients with advanced non-small cell lung cancer

  2013cites this paper
• Outpatient Chemotherapy and Clinical Pathway for Advanced Non-small-cell Lung Cancer

  2011cites this paper
• Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer.

  2010cites this paper
• A Phase II Study Directed by a Clinical Pathway for Carboplatin and Weekly Paclitaxel in Previously Untreated Patients with Unresectable Non-Small Cell Lung Cancer

  2010cites this paper
• 進行非小細胞肺癌に対するCarboplatin+weekly Paclitaxel併用療法の後ろ向き検討

  2010cites this paper
• A Phase II Feasibility Study of Weekly Paclitaxel in Heavily Pretreated Advanced Gastric Cancer Patients with Poor Performance Status

  2009cites this paper
• Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI.

  2009cites this paper
• A Feasibility Study of Postoperative Adjuvant Therapy of Carboplatin and Weekly Paclitaxel for Completely Resected Non-small Cell Lung Cancer

  2008cites this paper
• The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.

  2008cites this paper
• Gefitinib in advanced non‐small cell lung cancer: Clinical experience in patients of Asian origin

  2007cites this paper
• A phase II study of weekly paclitaxel combined with carboplatin for elderly patients with advanced non-small cell lung cancer.

  2006cites this paper
• Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer

  2006cites this paper
• Weekly Paclitaxel Combined with Monthly Carboplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

  2006cites this paper
• Phase II study of carboplatin and weekly paclitaxel in advanced non-small cell lung cancer.

  2006cites this paper